Table 3

The relationship between CD44v6 and integrin-β1 protein expression and clinical pathological features of patients with PC
Pathological features N CD44v6 protein expression P value Integrin-β1 protein expression P value
High Low High Low
Sex 0.201 0.269
  Male 27 14 (51.9%) 13 (48.1%) 15 (55.6%) 12 (44.4%)
  Female 27 10 (37.0%) 17 (63.0%) 12 (44.4%) 15 (55.6%)
Age 0.856 0.189
  ≤60 24 11 (45.8%) 13 (54.2%) 14 (58.3%) 10 (41.7%)
  >60 30 13 (43.3%) 17 (56.7%) 13 (43.3%) 17 (56.7%)
Tumor location 0.086 0.378
  Head and body PC 34 12 (35.3%) 22 (64.7%) 16 (47.1%) 18 (52.9%)
  Tail PC 20 12 (60.0%) 8 (40.0%) 11 (55.0%) 9 (45.0%)
Clinical stages 0.046 0.019
  I+II 21 6 (28.6%) 15 (71.4%) 6 (31.6%) 13 (68.4%)
  III+IV 33 18 (54.5%) 15 (45.5%) 21 (60.0%) 14 (40.0%)
Tumor differentiation 0.037 0.038
  Poorly and moderately 33 10 (30.3%) 23 (69.7%) 12 (36.4%) 21 (63.6%)
  Highly 21 14 (66.7%) 7 (33.3%) 15 (71.4%) 6 (28.6%)
Tumor size (diameter) 0.112 0.154
  ≤4 cm 25 8 (32.0%) 18 (68.0%) 11 (44.0%) 14 (56.0%)
  >4 cm 29 16 (55.2%) 12 (44.8%) 16 (55.2%) 13 (44.8%)
LNM 0.035 0.017
  Negative 20 5 (25.0%) 15 (75.0%) 7 (30.4%) 16 (69.6%)
  Positive 34 19 (55.9%) 15 (44.1%) 20 (69.0%) 9 (31.0%)
Liver metastasis 0.013 0.029
  Negative 24 5 (20.8%) 19 (79.2%) 7 (29.2%) 17 (71.8%)
  Positive 30 19 (63.3%) 11 (36.7%) 20 (66.7%) 10 (33.3%)
CA199(U/ml) 0.187 0.354
  ≤1000 18 6 (33.3%) 12 (66.7%) 8 (44.4%) 10 (55.6%)
  >1000 36 18 (50.0%) 18 (50.0%) 19 (52.8%) 17 (47.2%)
KPS 0.233 0.176
  ≤80 25 13 (52.0%) 12 (48.0%) 15 (60.0%) 10 (40.0%)
  >80 29 11 (37.9%) 18 (62.1%) 12 (41.4%) 17 (58.6%)

Zhou et al.

Zhou et al. Diagnostic Pathology 2013 8:146   doi:10.1186/1746-1596-8-146

Open Data